Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 12/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222089 | 0.89 | GPR52 (0.78) | GPR52SNCAGAA | |
| SCHEMBL1852679 | 0.89 | GPR52 (0.72) | GPR52FYN | |
| SCHEMBL3208741 | 0.89 | GPR52 (0.62) | GPR52SNCAL3MBTL1NPC1RAB9A | |
| SCHEMBL1849554 | 0.88 | GPR52 (0.63) | GPR52SNCAL3MBTL1NPC1RAB9A | |
| SCHEMBL1849493 | 0.87 | GPR52 (0.75) | GPR52FYN | |
| SCHEMBL1851771 | 0.87 | GPR52 (1.00) | GPR52 | |
| SCHEMBL1855788 | 0.86 | GPR52 (0.58) | GPR52SNCA | |
| SCHEMBL3212711 | 0.84 | GPR52 (0.55) | GPR52L3MBTL1NPC1RAB9A | |
| SCHEMBL13489414 | 0.81 | GPR52 (0.54) | GPR52FYNSNCANPC1RAB9A | |
| SCHEMBL1849555 | 0.80 | GPR52 (0.51) | GPR52NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885FYN 1500/4885SNCA 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.